公开(公告)号：WO1992017215A1

公开(公告)日：1992-10-15

申请号：PCT/EP1992000698

申请日：1992-03-27

Applicant: COCKBAIN, Julian, R., M. ,  NYCOMED SALUTAR, INC. ,  ALMÉN, Torsten ,  BERG, Arne ,  CHANG, C., Allen ,  DROEGE, Michael ,  DUGSTAD, Harald ,  FELLMAN, Jere, D. ,  KIM, Sook-Hui ,  KLAVENESS, Jo ,  ROCKLAGE, Scott, M. ,  RONGVED, Pål ,  SEGAL, Brent ,  WATSON, Alan, D.

Inventor： COCKBAIN, Julian, R., M. ,  NYCOMED SALUTAR, INC.

IPC: A61K49/04

CPC classification number: A61K49/0002 ,  A61K49/06 ,  A61K51/02 ,  A61K51/0482 ,  A61K2123/00 ,  C07F11/005 ,  C07F15/025

Abstract: An imaging contrast medium comprising a physiologically tolerable multinuclear complex (as defined in claim 1) is disclosed. The multinuclear complex contains at least two, but preferably three or more contrast enhancing atoms. For X-ray or ultrasound imaging techniques heavy metal atoms are used to enhance contrast, whereas in Magnetic Resonance Imaging paramagnetic metal atoms are contrast enhancing. Molybdenum and tungsten are preferred contrast enhancing atoms. The medium may also be used therapeutically.

Abstract translation: 公开了一种包含生理上可耐受的多核复合物（如权利要求1所定义）的成像造影剂。 多核络合物包含至少两个，但优选三个或更多对比增强原子。 对于X射线或超声成像技术，重金属原子用于增强对比度，而在磁共振成像顺磁金属原子是对比度增强。 钼和钨是优选的对比度增强原子。 培养基也可以治疗使用。

公开(公告)号：WO1991014460A1

公开(公告)日：1991-10-03

申请号：PCT/EP1991000587

申请日：1991-03-27

Applicant: COCKBAIN, Julian, Roderick, Michaelson ,  NYCOMED AS ,  BERG, Arne ,  ALMÉN, Torsten ,  KRAUTWURST, Klaus, Dieter ,  KIM, Sook-Hui ,  RONGVED, Pål ,  KLAVENESS, Jo ,  DUGSTAD, Harald

Inventor： COCKBAIN, Julian, Roderick, Michaelson ,  NYCOMED AS

IPC: A61K49/04

CPC classification number: C07F11/005 ,  A61K49/04 ,  A61K51/02 ,  A61K51/04 ,  A61K51/0482 ,  A61K2123/00 ,  Y10S514/836

Abstract: The invention relates to the use as contrast enhancing agents in medical imaging, especially X-ray imaging, of multinuclear complexes, i.e. complexes, such as those of W2O2( mu 2O)2, in which the complexed entity comprises at least two contrast enhancing atoms.

Abstract translation: 本发明涉及作为多核复合物的医学成像，特别是X射线成像中的对比增强剂的用途，例如复合物，例如W 2 O 2（mu 2 O）2的那些，其中复合实体包含至少两个对比度增强原子 。

公开(公告)号：WO2018048873A2

公开(公告)日：2018-03-15

申请号：PCT/US2017/050236

申请日：2017-09-06

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： CHAO, Philip Hong-Sean ,  VAN DAM, R. Michael

IPC: A61K51/04 ,  A61M1/00

CPC classification number: A61K51/02 ,  A61B6/037 ,  A61K51/0446 ,  A61K51/0459 ,  A61K51/0491 ,  B01L3/502753 ,  B01L2300/0681 ,  B01L2300/0883 ,  B01L2300/12 ,  C07B59/00

Abstract: A method of formulating or concentrating a radiolabeled molecule or compound includes providing a microfluidic device having a sample layer containing a microfluidic channel formed therein, a porous membrane having a pore size of less than 0.5 µm disposed on the sample layer and covering the microfluidic channel, and a gas flow layer having a gas-carrying channel formed therein, wherein the porous membrane is interposed between the sample layer and the gas flow layer. A fluid containing the radiolabeled molecule or compound is delivered into the microfluidic channel. Heat is applied to evaporate the fluid. A gas is passed through gas-carrying channel to remove evaporated fluid from the microfluidic device.

Abstract translation: 配制或浓缩放射性标记的分子或化合物的方法包括提供微流体装置，所述微流体装置具有其中形成有微流体通道的样品层，孔径小于0.5μm的多孔膜 在样品层上并覆盖微流体通道，以及在其中形成有气体携带通道的气流层，其中多孔膜置于样品层和气流层之间。 含有放射性标记的分子或化合物的液体被输送到微流体通道中。 施加热量以蒸发流体。 气体通过载气通道从微流体装置中除去蒸发的流体。

公开(公告)号：WO2017025496A1

公开(公告)日：2017-02-16

申请号：PCT/EP2016/068852

申请日：2016-08-08

Applicant: BAYER PHARMA AKTIENGESELLSCHAFT

Inventor： SCHOLZ, Arne

IPC: A61K51/00 ,  A61P35/00 ,  A61K39/395

CPC classification number: A61K51/02 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/2827 ,  A61K2300/00

Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an immune checkpoint inhibitor, and component B being a pharmaceutically acceptable salt of the alkaline-earth radionuclide radium-223, the combination being useful for the treatment or prophylaxis of cancer.

Abstract translation: 本发明涉及至少两种组分的组合，组分A和组分B，组分A是免疫检查点抑制剂，组分B是碱土金属核素镭-223的药学上可接受的盐，该组合可用于 治疗或预防癌症。

公开(公告)号：WO2017005648A1

公开(公告)日：2017-01-12

申请号：PCT/EP2016/065573

申请日：2016-07-01

Applicant: ONCOINVENT AS

Inventor： WESTRØM, Sara ,  LARSEN, Roy, Hartvig

IPC: A61K51/02 ,  A61K51/10 ,  A61K51/12 ,  A61P35/00 ,  A61K103/00

CPC classification number: A61K51/025 ,  A61K51/02 ,  A61K51/103 ,  A61K51/1093 ,  A61K51/1244 ,  C01F11/18 ,  C01P2004/64 ,  C01P2006/44

Abstract: The present invention relates to a particle or pharmaceutical composition comprising one, more particles or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. A particle comprising CaCO 3 , the alpha emitting radionuclide 224 Ra, and a 224 Ra radionuclide progeny is in particular disclosed. The particles are beneficial for use in the treatment of cancer.

Abstract translation: 本发明涉及一种颗粒或药物组合物，其包含一种，更多颗粒或包含可降解化合物和α发射放射性核素和/或产生α发射子的放射性核素的相同或不同颗粒的颗粒或悬浮液。 特别公开了包含CaCO 3，α发射放射性核素224Ra和224Ra放射性核素后代的颗粒。 该颗粒有益于用于治疗癌症。

公开(公告)号：WO2012162565A3

公开(公告)日：2013-06-13

申请号：PCT/US2012039474

申请日：2012-05-24

Applicant: CEL SCI CORP ,  ZIMMERMAN DANIEL H ,  TALOR EYAL ,  ROSENTHAL KENNETH

Inventor： ZIMMERMAN DANIEL H ,  TALOR EYAL ,  ROSENTHAL KENNETH

IPC: A61K39/395 ,  A61K38/16 ,  A61K38/17 ,  A61P35/00

CPC classification number: A61K39/00 ,  A61K35/12 ,  A61K38/162 ,  A61K39/0008 ,  A61K39/0011 ,  A61K47/646 ,  A61K47/68 ,  A61K47/6901 ,  A61K51/02 ,  A61K2039/5154

Abstract: The invention is related to peptide constructs, i.e., polypeptides obtained by linking together two or more peptides based on or derived from different molecules, which are useful in the treatment or prevention of cancer or the treatment of autoimmune diseases and compositions containing same, methods for producing same, and methods for using same; wherein the peptide constructs have the formula Pi-x-P2 where P2 is a peptide associated with forms of cancer or an autoimmune condition and Pi is a peptide which will bind to a class of immune cells such as dendritic cells. The peptide construct can cause the maturation of immature dendritic cells to a more mature state. The peptide construct or the more mature dendritic cells can be administered to a subject to modulate or to initiate an immune response against cancer cells, and can be used with dyes, radioisotopes, or therapeutic agents for detection of the immune target and/or treatment of cancer and autoimmune conditions.

Abstract translation: 本发明涉及肽构建体，即通过将两种或更多种基于或衍生自不同分子的肽连接在一起而获得的多肽，其可用于治疗或预防癌症或治疗自身免疫疾病和含有其的组合物，方法 生产方法和使用方法; 其中所述肽构建体具有式Pi-x-P2，其中P2是与癌症形式或自身免疫病症相关的肽，并且Pi是将结合一类免疫细胞如树突状细胞的肽。 肽结构可导致未成熟树突状细胞的成熟进入更成熟的状态。 肽构建体或更成熟的树突细胞可以施用于受试者以调节或引发针对癌细胞的免疫应答，并且可以与染料，放射性同位素或治疗剂一起用于检测免疫靶标和/或治疗 癌症和自身免疫病症。

公开(公告)号：WO2012143713A3

公开(公告)日：2013-02-07

申请号：PCT/GB2012050852

申请日：2012-04-18

Applicant: DSPI LTD ,  KNOX PETER

Inventor： KNOX PETER

IPC: A61K51/12 ,  A61P35/00

CPC classification number: A61K51/02 ,  A61K51/025 ,  A61K51/121

Abstract: The invention provides a method of treating a tumor or other lesion comprising introducing a solution comprising one or more radioactive isotopes directly into said tumour or other lesion in a mammal to effect in situ precipitation of a radioactive precipitate in the tumour or other lesion.

Abstract translation: 本发明提供了一种治疗肿瘤或其它病变的方法，包括将包含一种或多种放射性同位素的溶液直接引入哺乳动物的所述肿瘤或其他损伤中，以使肿瘤或其它病变中的放射性沉淀物原位沉淀。

公开(公告)号：WO2012110835A3

公开(公告)日：2012-10-26

申请号：PCT/HU2012000010

申请日：2012-02-15

Applicant: SEMMELWEIS EGYETEM ,  MATHE DOMOKOS ,  SZIGETI KRISZTIAN

Inventor： MATHE DOMOKOS ,  SZIGETI KRISZTIAN

IPC: A61K51/02 ,  A61K49/08 ,  A61K49/18 ,  A61K51/12 ,  B82Y15/00

CPC classification number: A61K49/0002 ,  A61K49/04 ,  A61K49/08 ,  A61K49/1836 ,  A61K51/02 ,  A61K51/1244 ,  B82Y30/00

Abstract: The invention relates to a Prussian Blue based nanoparticle comprising a Prussian Blue based metal core doped with one or more metal isotope and an organic biocompatible coating. The invention relates furthermore to a process for the preparation of said nanoparticle, and the use thereof as imaging contrast material or in the therapy.?

Abstract translation: 本发明涉及一种基于普鲁士蓝的纳米颗粒，其包含掺杂有一种或多种金属同位素和有机生物相容性涂层的普鲁士蓝基金属芯。 本发明还涉及制备所述纳米颗粒的方法及其作为成像对比材料或在治疗中的用途。

公开(公告)号：WO2011133216A3

公开(公告)日：2012-04-19

申请号：PCT/US2011000703

申请日：2011-04-20

Applicant: EINSTEIN COLL MED ,  CAL POLY POMONA FOUNDATION INC ,  CARRASCO NANCY ,  BELENITSKY MONIKA ,  MAESTAS MATTHEW J ,  ESKANDARI SEPEHR

Inventor： CARRASCO NANCY ,  BELENITSKY MONIKA ,  MAESTAS MATTHEW J ,  ESKANDARI SEPEHR

IPC: C07K1/00 ,  A61K48/00 ,  A61K51/00

CPC classification number: C07K14/705 ,  A61K31/198 ,  A61K33/18 ,  A61K38/00 ,  A61K48/005 ,  A61K51/02 ,  G01N33/56966 ,  A61K2300/00

Abstract: Disclosed are Na+/I- symporter (NIS) mutant proteins wherein glycine residue 93 is replaced with aspartic acid or glutamic acid, a method of preparing said mutant NIS protein, a transfection vector for a NIS mutant protein, and a pharmaceutical composition comprising said mutant NIS protein in a pharmaceutically acceptable carrier. The disclosure also provides a method of treating cancer or cancerous cells, comprising administering a therapeutically effective amount of a transfection vector for a NIS mutant protein or a pharmaceutical composition thereof, and administering a therapeutically effective amount of radioisotope. The disclosure further provides a method of imaging cells, comprising administering to the cells an effective amount of a transfection vector for a NIS mutant protein, administering a effective amount of imaging label, and imaging the cells.

Abstract translation: 公开了其中甘氨酸残基93被天冬氨酸或谷氨酸代替的Na + / I-对映体蛋白（NIS）突变蛋白，制备所述突变NIS蛋白的方法，NIS突变蛋白的转染载体和包含所述突变体 NIS蛋白在药学上可接受的载体中。 本公开还提供了治疗癌症或癌细胞的方法，其包括给予NIS突变蛋白或其药物组合物的治疗有效量的转染载体，以及施用治疗有效量的放射性同位素。 本公开进一步提供了一种对细胞进行成像的方法，包括向细胞施用有效量的NIS突变蛋白转染载体，施用有效量的成像标记物和成像细胞。

公开(公告)号：WO2011049405A3

公开(公告)日：2011-09-29

申请号：PCT/KR2010007287

申请日：2010-10-22

Applicant: KYUNGPOOK NAT UNIV IND ACAD ,  YOO JEONG-SOO ,  PARK JEONG CHAN

Inventor： YOO JEONG-SOO ,  PARK JEONG CHAN

IPC: A61K51/00 ,  A61K101/00 ,  A61K103/30 ,  A61P35/00

CPC classification number: G01T1/164 ,  A61K49/0002 ,  A61K49/0067 ,  A61K49/1857 ,  A61K51/02 ,  A61K51/025 ,  A61K51/0491 ,  A61K51/1051 ,  A61K51/1244 ,  G01T7/08

Abstract: The present invention relates to an optical imaging contrast agent, the use and a device thereof. The optical imaging contrast agent of the present invention does not need to comprise a separate fluorescent material or luminescent material to emit light, and can thus acquire an optical image without changing the physicochemical properties of an original molecule. The optical imaging contrast agent of the present invention can be used as an optical/nuclear medical dual imaging contrast agent in many cases, and enables the effects of treatment to be monitored from optical images concurrently with radiotherapy. In addition, when linked with a fluorescent material, the optical imaging contrast agent of the present invention can emit light from the fluorescent material with energy independently generated from the optical contrast agent without being supplied with energy from outside, and thus allows the amount of light to be increased and the tissue permeability to be enhanced.

Abstract translation: 本发明涉及一种光学成像造影剂，其用途和装置。 本发明的光学成像造影剂不需要包括单独的荧光材料或发光材料来发光，并且因此可以获得光学图像而不改变原始分子的物理化学性质。 本发明的光学成像造影剂在很多情况下可以用作光学/核医学双成像造影剂，并且能够在放疗的同时从光学图像监测治疗效果。 另外，本发明的光学成像造影剂在与荧光材料连接时，不用从外部供给能量就能够利用光造影剂独立产生的能量从荧光材料发射光，从而允许光量 增加，组织渗透性增强。